Kenneth Baillie

Chief Executive Officer

Kenneth Baillie, FRSE FMedSci, is transforming our understanding of life through the intersection of computational biology and critical care medicine. As Professor of Experimental Medicine at the University of Edinburgh and Co-Lead of the Baillie-Gifford Pandemic Science Hub, he bridges the gap between genomic discovery and clinical breakthroughs.

Professor Baillie spearheaded the world’s largest genome-wide association study (GWAS) on critical illness, leading to pivotal discoveries including the identification of baricitinib as an effective COVID-19 treatment. His innovative approach to biological research transcends traditional boundaries, with applications spanning medicine, agriculture, and environmental science.

A visionary leader who has secured over £100 million in career funding, Professor Baillie’s groundbreaking work appears in the world’s most prestigious scientific journals, including Nature, Science, NEJM, and The Lancet. As CEO of Multiscale, he is driving the development of an autonomously-learning computational model of life, leveraging his unique expertise in genomics, data science, and cross-species biological systems.